Growth and lipid metabolism in girls and young women with epilepsy during pubertal maturation

Epilepsia

Volumn 46, Issue 7, 2005, Pages 1114-1120

  Mikkonen, Kirsi ^a   Knip, Mikael ^b   Pakarinen, Arto J ^a   Lanning, Peter ^a   Isojärvi, Jouko I T ^a   Vainionpää, Leena K ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antiepileptic drugs; Children; Cholesterol; Epilepsy; Growth

Indexed keywords

CARBAMAZEPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXCARBAZEPINE; VALPROIC ACID;

ADOLESCENT; ARTICLE; BODY MASS; BODY WEIGHT; CHILD; CHILD GROWTH; CONTROLLED STUDY; EPILEPSY; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; PRIORITY JOURNAL; PUBERTY;

ADOLESCENT; ADULT; ANTICONVULSANTS; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CHILD; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; GROWTH; HUMANS; LIPID METABOLISM; LIPIDS; LONGITUDINAL STUDIES; PUBERTY; SEX FACTORS;

EID: 21844436521     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.34304.x     Document Type: Article

References (32)

1. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J 1981;283:577-81.
2. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
3. Rättyä J, Vainionpää L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103:588-93.
4. Kurlemann G, Benner T, Brämswig HJ. Adult height and target height in 111 boys and 98 girls treated for epilepsy during childhood. J Child Neurol 1997;12:513-5.
5. Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42:1141-7.
6. Novak GP, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14:490-5.
7. Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45:444-50.
8. Isojärvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
9. Isojärvi JI, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-51.
10. Eiris J, Novo-Rodriguez MI, Del Rio M, et al. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000;41:1-7.
11. Verrotti A, Basciani F, Domizio S, et al. Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 1998;19:364-7.
12. Sözüer DT, Atakil D, Dogu O, et al. Serum lipids in epileptic children treated with carbamazepine and valproate. Eur J Pediatr 1997;156:565-7.
13. Serdaroglu G, Kurul S, Tutuncuoglu S, et al. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003;28:37-41.
14. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
15. Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol 1990;32:213-20.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
17. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 1998;24:323-55.
18. Sorva R, Lankinen S, Tolppanen EM, et al. Variation of growth in height and weight of children, II: after infancy. Acta Paediatr Scand 1990;79:498-506.
19. Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43:1488-92.
20. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-62.
21. Macardle BM, McGowan ME, Greene SA, et al. Anticonvulsant drugs, growth, and development. Arch Dis Child 1987;62:615-7.
22. Biton V, Levisohn P, Hoyler S, et al. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol 2003;18:133-9.
23. Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003;28:126-9.
24. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997;24:240-4.
25. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis 1998;140:199-270.
26. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000;160:898-904.
27. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003;17:781-91.
28. Pylvänen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002;43:514-7.
29. Luef GJ, Lechleimer M, Bauer G, et al. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003;55:53-8.
30. Isojärvi JI, Pakarinen AJ, Rautio A, et al. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994;35:1217-20.
31. Isojärvi JI, Pakarinen AJ, Myllylä VV. Serum lipid levels during carbamazepine medication: a prospective study. Arch Neurol 1993;50:590-3.
32. Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine. Eur J Clin Pharmacol 1990;39:187-8.